World Rabies Day 2020 sustainable dog vaccination
World Rabies Day 2020 sustainable dog vaccination
Search
Boehringer expands production site in Greece
Boehringer expands production site in Greece for new medicine
License to develop new fibro-inflammatory disease treatments
License to develop new fibro-inflammatory disease treatments
Our Biotech Story | Bioxcellence | Boehringer Ingelheim
Discover our pioneering history & leadership in biotechnology, driving innovation in biopharmaceutical manufacturing & breakthrough therapies.
1948-1990: Going global
The Boehringer Ingelheim history from 1948-1990, with milestones
Boehringer acquires T3 Pharma
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Dominik Huber
Dominik Huber, Our Head of Upstream Manufacturing in Vienna, Dominik Huber, has built his entire, senior-level career with Boehringer Ingelheim.
Big molecules - Huge potential | Bioxcellence | Boehringer Ingelheim
Explore the potential of big molecules with BioXcellence, offering advanced biopharmaceutical production services to unlock new possibilities in healthcare.
Plasmid DNA Production | BioXcellence
Discover our range of plasmid DNA production solutions from research to GMP.
Work life balance
It's important that employees have a balance between professional and personal lives, so we offer various leave options and flexible working schedules.
opening-solids-launch-fabrik
Boehringer Ingelheim today opened a tablet factory at Ingelheim in the presence of the State Premier of Rhineland-Palatinate, Malu Dreyer.
Kicking off 2024 with five new R&D partnerships
We are kicking off 2024 with five new R&D partnerships to further enable and accelerate the company’s commitment to transform the lives of patients world-wide.
Advancing health equity for rural doctors in Mexico
Our virtual sales team helps doctors stay informed through digital education about the latest treatments, regardless of their location
Boehringer expands cancer research at Vienna site
Boehringer Ingelheim expands cancer research at its Vienna site
Ethical Business Practices
Suppliers shall conduct their business in an ethical manner and act with integrity.
Innovation in medicinal chemistry
Darryl McConnell, Research Site Head, Austria and Jürgen Mack, Medicinal Chemistry, explain how we are working to unlock unsolved diseases
PREVEXXION® RN: Marek’s disease vaccine available in EU UK
Boehringer Ingelheim is pleased to announce the launch of the next generation of Marek’s disease vaccines is now available in the EU.
BI_X_Shanghai
Boehringer Ingelheim opens a second branch of its digital lab in Shanghai
Boehringer Ingelheim partners with GNA Biosolutions
Boehringer Ingelheim partners with GNA Biosolutions to develop African swine fever diagnostic test.
2020 European PRRS Research Award sponsorship
2020 European PRRS Research Award: Boehringer Ingelheim calls for submissions
European Election: Europe needs our vote
This week, over 400 million citizens from the 27 European Union (EU) Member States will be able to elect a new European Parliament. Our vote can help to make a better and stronger Europe..
Smart Factory: Digitalizing production facilities
How our digitalized production facilities help our colleagues and patients
Boehringer receives SBTi validation for CO2 reduction targets
Boehringer Ingelheim receives SBTi validation for CO2 reduction targets
Data science, agile working, UX design: our evolving IT careers
Meet our IT colleagues working in the fields of user experience, data science and agile development
Phase 1 start of treatment for Geographic Atrophy patients
Boehringer initiates Phase 1 evaluation of BI 771716 a treatment for preserving vision of people living with geographic atrophy (GA)